Down 17%, does the GSK share price scream buy?

It has been far from a smooth journey for the GSK share price recently. But this Fool likes the look of the stock now that it is down nearly 20%.

| More on:

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a turbulent 12 months for the GSK (LSE: GSK) share price. Back then it was trading for 1,316.6p. Today, it’s 1,509.9p, or 14.7% higher.

But that doesn’t paint the full picture. During that time, the stock has been on a roller-coaster ride. And shareholders have certainly had to brace themselves at points.

Right now, the stock is down around 17% from its 52-week high after a recent tumble. I’m sensing a buying opportunity.

An uncertain period

Before I explain why, it’s best to explore what’s been behind the volatility that its share price has been experiencing. There’s one main factor.

It’s down to potential litigation related to Zantac, a heartburn drug that was removed from the market in 2019 after being linked to cancer. While this has been ongoing for a few years, there have been a couple of developments this year.

The most recent update was the catalyst for its share price decline. A Delaware judge ruled in favour of more than 70,000 lawsuits related to the drug and its link to causing cancer going forward. Its share price slid around 11% on the back of the news.

It hasn’t got much better from there. Since then, the stock has continued on its spiral. It has lost a further 5.5% of its value despite GSK saying it will appeal and “vigorously defend itself” against the claims.


Yet despite the uncertainty this creates, I think GSK looks like a bargain. Let’s start with its attractive valuation.

It currently trades on a price-to-earnings (P/E) ratio of 13.8 and a forward P/E of 10.3. I think that looks like good value. Its long-term historical average is closer to 15, suggesting there may be growing room in today’s share price.

What’s more, that’s below the global sector average. It’s significantly cheaper than its rival AstraZeneca, which is currently trading on a P/E ratio of 37.8.


Its falling share price also translates to a meatier dividend yield. It pays out 3.9%, above the FTSE 100 average (3.6%). Last year its dividend payment rose 5.5% to 58p. The business has given 2024 guidance of a 60p dividend, a 3.4% rise.

Alongside its yield, I also like the stability it can provide over the long term as it’s a defensive stock. That may sound contradictory given its recent volatility. But with it providing essential needs, such as vaccines and medicines, this means it’ll always be in demand regardless of external factors such as economic uncertainty. We saw this last year when its revenue and earnings grew 3.4% and 11%, respectively.

I’d buy

I’m fully aware of the risk with Zantac, which is large. So much so that broker UBS recently downgraded its rating for the stock from ‘buy’ to ‘neutral’. These sorts of legal complications are a major risk when investing in pharmaceutical stocks.

But even so, despite downgrading the stock, UBS alluded to GSK having an attractive valuation, and that’s what’s drawing me in. On top of that, the major bank Citi put a ‘buy’ rating on the stock earlier this month.

I think now could be a smart time for investors to consider cheap GSK shares. If I had the cash, I’d happily buy the stock today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I reckon these 2 penny shares are hidden gems worth a closer look!

Some penny shares are well-known, whereas many others go under the radar, but that doesn’t necessarily mean they aren’t potentially…

Read more »

Investing Articles

Just released: our 3 best dividend-focused stocks to buy before August [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

2 FTSE 100 shares with blockbuster yields investors should consider buying

Our writer has noticed that these FTSE 100 shares offer mammoth dividend yields, and reckons investors should take a closer…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Down 36% and yielding 7.8%, is this FTSE 250 share a bargain?

Christopher Ruane looks at a FTSE 250 share with a sizeable dividend yield and a recent record of dividend growth.…

Read more »

Investing Articles

Is Barclays one of the FTSE 100’s best bargain stocks?

Right now, Barclays' shares are cheaper than those of FTSE 100 rival stocks Lloyds and NatWest. So should I buy…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Is a takeover offer about to boost the Rentokil stock price, and should I buy?

The Rentokil share price is up 10% on takeover rumours. Is it a stock to buy or one to be…

Read more »

Investing Articles

Here’s my Rolls-Royce dividend forecast for 2024-27!

Our writer considers whether the Rolls-Royce dividend might be reinstated in coming years, based on financial performance and stated payout…

Read more »

Investing Articles

What would I do if Rolls-Royce shares plunged 50%? History suggests a big decline is coming

While Rolls-Royce shares have delivered massive outperformance in recent years, they also have a history of significant declines.

Read more »